D'Arena, Giovanni <br/><br/>
Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.  [electronic resource] 

 -  Leukemia & lymphoma  11 2017 
 - 2633-2641 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Observational Study 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.1080/10428194.2017.1306648  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Immunological--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Autoimmune Diseases--drug therapy<br/>Drug-Related Side Effects and Adverse Reactions--blood<br/>Female<br/>Hematologic Neoplasms--drug therapy<br/>Humans<br/>Infusions, Intravenous<br/>Male<br/>Middle Aged<br/>Prognosis<br/>Retrospective Studies<br/>Risk Factors<br/>Rituximab--administration & dosage<br/>Young Adult